Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE ALLERGY versus HISTAFED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE ALLERGY versus HISTAFED.
AZELASTINE HYDROCHLORIDE ALLERGY vs HISTAFED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine with mast cell stabilizing properties; selectively antagonizes histamine H1 receptors, reducing nasal pruritus, sneezing, rhinorrhea, and ocular symptoms.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
One spray (137 mcg) per nostril twice daily (total 548 mcg/day). Intranasal route.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
None Documented
None Documented
The terminal elimination half-life is approximately 22 hours (range 16-26 hours) at steady state, supporting twice-daily dosing. The half-life may be prolonged in elderly patients or those with hepatic impairment.
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Azelastine is primarily eliminated via renal excretion (approximately 75% as metabolites, <10% unchanged) and fecal excretion (approximately 25%) after oral administration. Biliary excretion is minimal.
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination